ICJR Interviews: Evaluating Efficacy of Topical vs. Intravenous TXA

    Kristoff Corten, MD, PhD, and his colleagues from Ziekenhuis Oost-Limburg in Genk, Belgium, have shown that topical tranexamic acid (TXA) is as effective as intravenous (IV) TXA in reducing blood loss following total hip arthroplasty through the direct anterior approach.

    Before conducting this head-to-head trial with 120 patients, Dr. Corten and his colleagues established the most effective means of delivering TXA topically, which they found to be intra-articular administration of 3 grams of TXA through a surgical drain that was closed after administration and then opened 2 hours later.

    They used this technique when comparing topical administration just after wound closure with IV administration of 1.5 grams of TXA just before wound closure. Patients in the IV TXA group also had a surgical drain that was opened 2 hours after wound closure.

    No differences were detected between groups in the primary endpoint of blood loss or in the secondary endpoints of length of stay and number of units of blood transfused.

    Click the image above to hear Dr. Corten discuss the study, “Topical Compared to Intravenous Tranexamic Acid in Total Hip Arthroplasty – A Prospective Randomized Trial” (Paper 409), which was presented at the 2016 Annual Meeting of the American Academy of Orthopaedic Surgeons in Orlando.

    Producer: Susan Doan-Johnson; Director: Michael Bugera; Post Production: Charles J. Maynard